INSPIRE topline results: Skyrizi achieves clinical remission in UC at 12 weeks

Topline findings from the phase 3 INSPIRE induction trial showed that Skyrizi, met the primary endpoint of achieving clinical remission at 12 weeks in adults with moderately to severely active ulcerative colitis, AbbVie announced.In addition, risankizumab (Skyrizi, AbbVie), an interleukin-23 inhibitor, achieved all secondary endpoints including clinical, endoscopic and histologic outcomes.“Our commitment to people living with gastroenterological conditions continues to grow,” Roopal Thakkar, MD, senior vice president, development, regulatory affairs and chief medical officer atRead More

Generated by Feedzy